<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01721538</url>
  </required_header>
  <id_info>
    <org_study_id>SCENARIO OP1</org_study_id>
    <nct_id>NCT01721538</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction</brief_title>
  <acronym>SCENARIO</acronym>
  <official_title>Secondary Prevention of Stroke Through Participation in the Non-drug Therapeutic Weight Reduction Program: A Single-blinded Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Von Behring-Röntgen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary
      prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with
      two arms. The therapy arm is participating in a comprehensive weight reducing program,
      whereas the control group takes part in a lecture on healthy nutrition. The primary study
      objective is to assess the efficacy of non-drug therapeutic weight reduction in the secondary
      prevention of stroke. Secondary objectives are functional outcome, cognitive status, post
      stroke depression, and health-related quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the number of deaths or major vascular events defined as stroke, TIA, myocardial infarction or hospitalization due to angina pectoris, which occur between the randomization and last follow-up.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>18 months</time_frame>
    <description>Functional outcome as measured by the modified Rankin Scale (mRS), NIH Stroke Scale (NIHSS) and Barthel Index (BI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive deficits</measure>
    <time_frame>18 months</time_frame>
    <description>Cognitive deficits in terms of vascular dementia as measured by the Structural Interview for diagnosis of Alzheimer dementia and multi-infarct dementia (SIDAM), the Vascular Dementia Assessment Scale cognitive subscale (VADAS-Cog), Stroop test and the Trail Makin Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post stroke depression</measure>
    <time_frame>18 months</time_frame>
    <description>Post stroke depression as measured by Beck Depression Inventar (BDI II) and health-related quality of life (HrQoL) as measured by the EuroQol (EQ5D, visual analogue scale), Stroke Specific Quality of Life Scale, Stroke Impact Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of arterial hypertension, diabetes mellitus and hyperlipidemia</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-drug therapeutic weight reduction program (15 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lecture on healthy nutrition (1 hour)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Weight reduction program</intervention_name>
    <arm_group_label>Therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lecture on healthy nutrition</intervention_name>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ischemic stroke

          -  Age: 20 - 85 years

          -  BMI ≥ 25.0 kg/m² or waist circumference in men ≥ 94cm and in women ≥ 80cm

          -  Functional impairment, which would allow to participate in weight reduction program
             (mRS 0-4, NIHSS 0-12)

          -  Patient must be capable of understanding informed consent

          -  Written informed consent for participation in the study

        Exclusion Criteria:

          -  Intracerebral hemorrhage as primary cause of stroke (secondary hemorrhage is not an
             exclusion criterion)

          -  Speech disturbance (aphasia or sever dysarthria)

          -  Dimming of consciousness

          -  Stroke due to arterial dissection or coagulation disorder

          -  Drug-related weight changes during previous 3 months

          -  Changes in appetite influencing medication listed in appendix during previous 3 months

          -  Bariatric surgery in the past

          -  Diabetes mellitus with a history of severe ketoacidosis

          -  Pregnancy or nursing

          -  Severe co-morbid disorders, e.g.:

               -  AV-Block ≥ 2nd degree

               -  Heart insufficiency (NYHA &gt; 2)

               -  Pericarditis, pericardial effusion

               -  Severe kidney insufficiency (Creatinine &gt; 3 mg/dl; Urea &gt; 150 mg/dl)

               -  Hepatic insufficiency (GOT &gt; 3 x ULN; GPT &gt; 3 x ULN)

               -  Severe psychiatric disease within the last six months (psychosis, suicide
                  attempts)

               -  Chronic alcohol addiction or drug addiction

               -  HIV- or hepatitis infection

               -  Bleeding peptic ulcer (unless there is radiological evidence of healing 6 months
                  prior to start of obesity program)

          -  Cognitive impairment with MMSE &lt; 20

          -  Depression with BDI &gt; 20

          -  Patients who are unable to give consent to study participation (MMSE &lt; 20, aphasia)

          -  Recurrent stroke or myocardial infarction in the period between screening for study
             participation and start of weight reduction program

          -  Simultaneous participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yaroslav Winter, MD</last_name>
    <phone>00496421-5865200</phone>
    <email>wintery@med.uni-marburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, Philipps-University Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winter Yaroslav, MD</last_name>
      <phone>004964215865200</phone>
      <email>wintery@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Yaroslav Winter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J, Back T. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke. 2008 Dec;39(12):3145-51. doi: 10.1161/STROKEAHA.108.523001. Epub 2008 Aug 14.</citation>
    <PMID>18703800</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2012</study_first_submitted>
  <study_first_submitted_qc>November 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2012</study_first_posted>
  <last_update_submitted>November 2, 2012</last_update_submitted>
  <last_update_submitted_qc>November 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Yaroslav Winter</investigator_full_name>
    <investigator_title>Neurologist and Research Fellow</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>prevention</keyword>
  <keyword>obesity</keyword>
  <keyword>weight reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

